Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
09/2003
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003013537A3 Irinotecan for treatment of cancer
09/25/2003WO2003013535A3 Use of irinotecan for improved treatment of cancer based on mdr1
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2002102375A3 Imidazole derivatives for modulating sodium channels
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002024910A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/25/2003US20030181706 Inflammation-associated polynucleotides
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181518 Compositions and methods for treating cystic fibrosis
09/25/2003US20030181514 Therapeutic compounds and methods
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181506 Hetercyclic carboxy compounds such as alpha-methyl-2-naphthalene-methyl 2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate used to selectively regulate induction of cytotoxic effecter macrophages
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181487 Salts of benzimidazole compound and use thereof
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants
09/25/2003US20030181457 Tertiary amides used as preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase, for prophylaxis of cardiovascular and sexual disorders
09/25/2003US20030181456 Heterocyclic amines used as antiemetics for prophylaxis of irritable bowel syndrome constipation, diarrhea, dyspepsia, nausea or vomiting
09/25/2003US20030181454 Nitrogen compounds and prodrugs used as type-II secretory phospholipase(sPLA2) agonists or antagonists, for prevention cancer, cirrhosis, Alzheimer's disease and/or arteriosclerosis
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181446 Novel N-acylated heterocycles
09/25/2003US20030181444 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181420 Modulators of LXR
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof
09/25/2003US20030181394 Carbobydrates such as alpha-D-galactopyranosyl-1,2-glycerol and/or isomers, obtained by solvent extraction from algae, for use as viricides or anticarcinogenic agents
09/25/2003US20030181390 Sustained release of aminobutyric acid using prodrugs such as L-1-naphthylalanine-gabapentin, administered for prophylaxis of nervous system disorders, as anxiolytics, antidepressants or antiinflammatory agents; drug delivery
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181360 Human TSLP DNA and polypeptides
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180404 Methods of treating clinical diseases with isoflavones
09/25/2003US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
09/25/2003US20030180394 Extracts from sophora species, method for producing the same and their use
09/25/2003US20030180381 Cobalt compound; therapy for Cmpylobacter
09/25/2003US20030180360 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
09/25/2003US20030180315 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
09/25/2003US20030180301 Prevention organ rejection; induction immunology response; reduce fibrosis
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180275 Human serpin polypeptides
09/25/2003US20030180260 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
09/25/2003CA2488928A1 Method of modulating inflammatory response
09/25/2003CA2479676A1 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003CA2479510A1 Primitive and proximal hepatic stem cells
09/25/2003CA2479352A1 Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient
09/25/2003CA2479350A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
09/25/2003CA2479246A1 Method for overexpression of zwitterionic polysaccharides
09/25/2003CA2479222A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/25/2003CA2479152A1 Methods of inducing differentiation of stem cells into a specific cell lineage
09/25/2003CA2479151A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003CA2479141A1 Pyridone derivatives
09/25/2003CA2478803A1 Methods of modulating cd200 receptors
09/25/2003CA2478795A1 Use of rapamycin for inhibiting cell death
09/25/2003CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
09/25/2003CA2478653A1 Methods of treatment with selective ep4 receptor agonists
09/25/2003CA2478294A1 Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
09/25/2003CA2478211A1 Nk1 antagonists
09/25/2003CA2477832A1 Methods of treating diabetes using pde 11a inhibitors
09/25/2003CA2476746A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/24/2003EP1346982A1 Vla-4 inhibitors
09/24/2003EP1346724A1 Remedies for hepatitis c
09/24/2003EP1346056A1 Methods for the production of multimeric proteins, and related compositions
09/24/2003EP1346055A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
09/24/2003EP1346053A2 Polynucleotides encoding human phosphatases
09/24/2003EP1346051A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
09/24/2003EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
09/24/2003EP1345938A1 Tricyclic crf receptor antagonists
09/24/2003EP1345937A1 Quinuclidine carbamate derivatives and their use as m3 antagonists
09/24/2003EP1345933A2 Process for making substituted 8-arylquinolinium benzenesulfonate
09/24/2003EP1345930A2 Pharmaceutical compounds
09/24/2003EP1345929A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345928A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345927A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345926A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345925A2 Pyrazole compounds useful as protein kinase inhibitors
1 ... 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 ... 1258